4don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the ...
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...
Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback